Hypertension and renal injury in experimental polycystic kidney disease

Kidney International

Volumn 56, Issue 6, 1999, Pages 2181-2190

  Kennefick, Thomas M ^a   Al Nimri, Muna A ^a   Oyama, Terry T ^a   Thompson, Michele M ^a   Kelly, Francis J ^a   Chapman, Justin G ^a   Anderson, Sharon ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Angiotensin; Hydralazine; Interstitial fibrosis; PKD; Progressive renal disease

Indexed keywords

ANGIOTENSIN; CREATININE; ENALAPRILAT; HYDRALAZINE; M PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY INJURY; KIDNEY PLASMA FLOW; KIDNEY POLYCYSTIC DISEASE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION;

EID: 0033456256     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00783.x     Document Type: Article

References (51)

1. 1. Grantham JJ: The etiology, pathogenesis and treatment of autosomal polycystic disease: Recent advances. Am J Kidney Dis 28:788-803, 1996
2. 2. Gabow PA: Autosomal dominant polycystic kidney disease. N Engl J Med 329:332-342, 1993
3. 3. Johnson AM, Gabow PA: Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 8:1560-1567, 1997
4. 4. Murcia NS, Sweeney WE Jr, Avner ED: New insights into the molecular pathophysiology of polycystic kidney disease. Kidney Int 55:1187-1197, 1999
5. 5. European Polycystic Kidney Disease Consortium: The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell 77:881-894, 1994
6. 6. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow P, Perides A, Kimberling WJ, Breuning MH, Deltas CC, Peters DJM, Somlo S: PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272:1339-1342, 1996
7. 7. Gabow PA, Ikle DW, Holmes JH: Polycystic kidney disease: Prospective analysis of non-azotemic patients and family members. Ann Int Med 101:238-247, 1984
8. 8. Gabow PA, Johnson AM, Kaehny WD: Factors affecting the progression of renal disease in autosomal dominant polycystic kidney disease. Kidney Int 41:1311-1319, 1992
9. 9. Bell PE, Hossack KF, Gabow PA: Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 34:683-690, 1988
10. 10. Chapman AB, Gabow PA: Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 52(Suppl 61):S71-S73, 1997
11. 11. Gabow PA, Chapman AB, Johnson AM, Tangel DJ, Duley IT, Kaehny WD, Manco-Johnson M, Schrier RW: Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38:1177-1180, 1990
12. 12. Cornell SH: Angiography in polycystic disease of the kidneys. J Urol 103:24-26, 1970
13. 13. Torres VE, Wilson DM, Offord KP, Burnett JC, Romero JC: Natriuretic response to expansion in polycystic kidney disease. Mayo Clin Proc 64:509-515, 1989
14. 14. Torres VE, Wilson DM, Burnett JC: Effect of inhibition of converting enzyme on renal hemodynamics and sodium management. Mayo Clin Proc 66:1010-1017, 1991
15. 15. Zeier M, Fehrenbach P, Geberth S, Möhring K, Waldherr R, Ritz E: Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 42:1259-1265, 1992
16. 16. Chapman AB, Johnson A, Gabow PA, Schrier RW: The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 323:1091-1096, 1990
17. 17. Barrett BJ, Foley R, Morgan J: Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 46:1118-1123, 1994
18. 18. Watson ML, MacNicol AM, Allan PL, Wright AF: Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int 41:206-210, 1992
19. 19. Fox J, Guan S, Hymel AA, Navar LG: Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol 262:F902-F909, 1992
20. 20. Cowley BD, Gudapaty S, Kraybill AL: Autosomal dominant polycystic kidney disease in the rat. Kidney Int 43:522-534, 1993
21. 21. Schäfer K, Gretz N, Bader M, Oberbäumer I, Eckardt K-U, Kriz W, Bachmann S: Characterization of the Han:SPRD rat model for hereditary polycystic disease. Kidney Int 46:134-152, 1994
22. 22. Ketth DS, Torres VE, Johnson CM, Holley KE: Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis 24:491-498, 1994
23. 23. Ogborn MR, Sareen S, Pinette G: Cilazapril delays progression of hypertension and uremia in rat polycystic kidney disease. Am J Kidney Dis 26:942-946, 1995
24. 24. Harrap SB, Davies DL, MacNicol AM, Dominiczak AF, Fraser R, Wright AF, Watson ML, Briggs JD: Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 40:501-508, 1991
25. 25. Barendregt JNM, Florijn KW, Muizert Y, Chang PC: Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion. Nephrol Dial Transplant 10:1332-1341, 1995
26. 26. Munemura C, Uemasu J, Kawasaki H: Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: Possible evidence of heterogeneity in cystogenesis. Am J Kidney Dis 24:561-568, 1994
27. 27. Giusti R, Neri M, Angelini D, Carlini A, Fiorini I, Bigongiari P, Antonelli A: Plasma concentration of endothelin and arterial pressure in patients with ADPKD. Contrib Nephrol 115:118-121, 1995
28. 28. Nakamura T, Ebihara I, Fukui M, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, Koide H: Increased endothelin and endothelin receptor mRNA expression in polycystic kidneys of cpk mice. J Am Soc Nephrol 4:1064-1072, 1993
29. 29. Hocher B, Zart R, Schwarz A, Vogt V, Braun C, Thöne-Reineke C, Braun N, Neumayer H-H, Koppenhagen K, Bauer C, Rohmeiss P: Renal endothelin system in polycystic kidney disease. J Am Soc Nephrol 9:1169-1177, 1998
30. 30. Richards WG, Sweeney WE, Yoder BK, Wilkinson JE, Woychik RP, Avner ED: Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest 101:935-939, 1998
31. 31. Harris RC, Hoover RL, Jacobson HR, Badr KF: Evidence for glomerular actions of epidermal growth factor in the rat. J Clin Invest 82:1028-1039, 1988
32. 32. Harris RC, Cheng H-F: The intrarenal renin-angiotensin system: A paracrine system for the local control of renal function separate from the systemic axis. Exp Nephrol 4(Suppl 1):2-7, 1996
33. 33. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986
34. 34. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
35. 35. Diamond JR, Anderson S: Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis: Amelioration by angiotensin I converting enzyme inhibition. Am J Pathol 137:1323-1332, 1990
36. 36. Shihab FS, Bennett WM, Tanner AM, Andoh TF: Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy. Kidney Int 52:660-673, 1997
37. 37. Paul LC, Benediktsson H: Post-transplant hypertension and chronic renal allograft failure. Kidney Int 48(Suppl 52):S34-S37, 1995
38. 38. Elzinga UW, Rosen S, Bennett WM: Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephrotoxicity: Role of sodium intake. J Am Soc Nephrol 4:214-221, 1993
39. 39. Anderson S, Jung FF, Ingelfinger JR: Renin-angiotensin system in diabetic rats: Functional, immunohistochemical, and molecular biologic correlations. Am J Physiol 265:F477-F486, 1993
40. 40. Baboolal K, Meyer TW: The effect of acute angiotensin II blockade on renal function in rats with reduced renal mass. Kidney Int 46:980-985, 1994
41. 41. De'Oliveira JM, Price DA, Fisher ND, Allan DR, McKnight JA, Williams GH, Hollenberg NK: Autonomy of the renin system in type II diabetes mellitus: Dietary sodium and the renal hemodynamic responses to ACE inhibition. Kidney Int 52:771-777, 1997
42. 42. Graham PC, Lindop GBM: The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int 33:1084-1090, 1988
43. 43. Torres VE, Donovan KA, Scicli G, Holley KE, Thibodeau SN, Carretero OA, Inagami T, McAteer JA, Johnson CM: Synthesis of renin by tubulocystic epithelium in autosomal dominant polycystic kidney disease. Kidney Int 42:364-373, 1992
44. 44. Anderson S, Rennke HG, Garcia DL, Brenner BM: Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36:526-536, 1989
45. 45. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
46. 46. Maschio G, Alberti D, Janin G, Locateli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zuchelli P: Angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group: Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
47. 47. Anderson S, Rennke HG, Zatz R: Glomerular adaptations with normal aging and with long-term converting enzyme inhibition in the rat. Am J Physiol 267:F35-F43, 1994
48. 4R. Modification of Diet in Renal Disease Study Group: Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 5:2037-2047, 1995
49. 49. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:1349-1354, 1994
50. 50. Gonzalo A, Gallego A, Ortuño J: Proteinuria and hypertension in autosomal dominant polycystic kidney disease. (letter) Nephron 73:359, 1996
51. 51. Chapman AB, Gabow PA, Schrier RW: Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease. Ann Intern Med 115:769-773, 1991